NCT05417191

Brief Summary

The trial was a double-blind randomized dietary intervention study with a 1:1 allocation ratio, conducted in accordance with the Declaration of Helsinki. This study compared two treatments, i.e., farmed fish fed with olive pomace enriched diet (enriched fish; EF) versus farmed fish fed with fish oil diet (conventional fish; CF), using a crossover design. The study lasted 22 weeks; treatment period one (8 weeks, mid-January-end of March), washout period (6 weeks), and treatment period two (8 weeks, mid-May-end of July). The participants were equally distributed to the two treatments along treatment periods. Eligible subjects were all adults aged between 30 and 65 years old with a body mass index (BMI) between 24.0 and 31.0 kg/m2 who met the eligibility criteria for habitual fish consumption (\<150 g of cooked fish per week). Exclusion criteria were pregnancy, current or recent weight loss effort, use of dietary supplements and being under treatment for any medical disorder. Subjects were allowed to use medical treatment for thyroid gland disorders, iron or folic acid supplements, contraceptives or hormone replacement therapy (HRT) for women, provided they would continue receiving their medication throughout the study. The aim of the study was to evaluate the effects of consumption of fillets from differently fed farmed gilthead sea bream on markers of cardiometabolic health such as platelet aggregation, circulating haemostatic markers, markers of inflammation and oxidative stress.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
38

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2013

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2014

Completed
8.3 years until next milestone

First Submitted

Initial submission to the registry

June 9, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 14, 2022

Completed
Last Updated

June 14, 2022

Status Verified

June 1, 2022

Enrollment Period

12 months

First QC Date

June 9, 2022

Last Update Submit

June 9, 2022

Conditions

Keywords

fishsea breamdietary interventionolive oilplatelet aggregationthrombosisinflammationcardioprotection

Outcome Measures

Primary Outcomes (5)

  • Change from baseline of adenosine diphosphate-induced platelet aggregation at 8 weeks

    Efficiency concentration fifty of adenosine diphosphate-induced platelet aggregation (microM) will be assessed by light transmittance aggregometry

    0 (baseline) and 8 weeks

  • Change from baseline of platelet activating factor-induced platelet aggregation at 8 weeks

    Efficiency concentration fifty of platelet activating factor-induced platelet aggregation (microM) will be assessed by light transmittance aggregometry

    0 (baseline) and 8 weeks

  • Change from baseline of thrombin-induced platelet aggregation at 8 weeks

    Efficiency concentration fifty of thrombin-induced platelet aggregation (microM) will be assessed by light transmittance aggregometry

    0 (baseline) and 8 weeks

  • Change from baseline in of plasminogen activator inhibitor-1 activity at 8 weeks

    Plasminogen activator inhibitor-1 activity (mAU/mL) will be measured in blood samples using commercially available ELISA kits

    0 (baseline) and 8 weeks

  • Change from baseline in soluble P-selectin levels at 8 weeks

    Soluble P-selectin levels (ng/mL) will be measured in blood samples using commercially available ELISA kits

    0 (baseline) and 8 weeks

Study Arms (2)

Conventional fish

ACTIVE COMPARATOR

This arm will consume 2 portions of gilthead seabream fed with conventional diet. Each portion weighed on average 380 g (raw, quantity of edible fillet approximately 170 g). Participants were instructed to consume fish twice weekly, one portion at a time.

Behavioral: Conventional fish

Enriched fish

EXPERIMENTAL

This arm will consume 2 portions of gilthead seabream fed with olive pomace enriched diet. Each portion weighed on average 380 g (raw, quantity of edible fillet approximately 170 g). Participants were instructed to consume fish twice weekly, one portion at a time.

Behavioral: Enriched fish

Interventions

Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using standard procedures. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.

Conventional fish
Enriched fishBEHAVIORAL

Participants initially randomized to this intervention arm will be provided with conventional sea bream fillets and will be asked to consume them twice weekly for 8 weeks. Conventional sea bream fillets will be produced by a fish farming company using a diet enriched with olive pomace. Participants will also be instructed to keep the reception of prescribed medications and dietary supplements stable and not to change their lifestyle habits (e.g. other dietary habits besides fish consumption, physical activity habits or sleep habits) during the intervention. After a 6-week wash-out period (no fish consumption), participants will cross over to the other intervention arm.

Enriched fish

Eligibility Criteria

Age30 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 30-65 years old
  • Body Mass Index between 24-31 kg/m\^2
  • Habitual fish consumption: \<150 g of cooked fish per week

You may not qualify if:

  • Pregnancy
  • Current or recent weight loss effort
  • Use of dietary supplements
  • Being under treatment for any medical disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University

Kallithea, Attica, 17671, Greece

Location

Related Publications (1)

  • Ntzouvani A, Antonopoulou S, Fragopoulou E, Kontogianni MD, Nomikos T, Mikellidi A, Xanthopoulou Mu, Kalogeropoulos N, Panagiotakos D. Effect of Differently Fed Farmed Gilthead Sea Bream Consumption on Platelet Aggregation and Circulating Haemostatic Markers among Apparently Healthy Adults: A Double-Blind Randomized Crossover Trial. Nutrients. 2021 Jan 20;13(2):286. doi: 10.3390/nu13020286.

    PMID: 33498445BACKGROUND

MeSH Terms

Conditions

ThrombosisInflammation

Condition Hierarchy (Ancestors)

Embolism and ThrombosisVascular DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Smaragdi Antonopoulou, PhD

    Department of Nutrition and Dietetics, Harokopio University

    PRINCIPAL INVESTIGATOR
  • Elizabeth Fragopoulou, PhD

    Department of Nutrition and Dietetics, Harokopio University

    STUDY CHAIR
  • Tzortzis Nomikos, PhD

    Department of Nutrition and Dietetics, Harokopio University

    STUDY CHAIR
  • Meropi D Kontogianni, PhD

    Department of Nutrition and Dietetics, Harokopio University

    STUDY CHAIR
  • Michael Georgoulis, PhD

    Department of Nutrition and Dietetics, Harokopio University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor in Biochemistry

Study Record Dates

First Submitted

June 9, 2022

First Posted

June 14, 2022

Study Start

December 1, 2012

Primary Completion

November 30, 2013

Study Completion

February 28, 2014

Last Updated

June 14, 2022

Record last verified: 2022-06

Data Sharing

IPD Sharing
Will share

Deidentified individual participant data will be shared to investigators for the purpose of individual participant data meta-analysis, provided that the proposed use of the data has been approved by the Study Principal Investigator. Proposals should be directed to antonop@hua.gr. To gain access, data requestors will need to sign a data access agreement.

Locations